What Is VIP Peptide? Vasoactive Intestinal Peptide Research Overview

VIP has been studied intensively as an endogenous neuropeptide since the 1970s — yet most of the therapeutic interest sits in contexts where systemic delivery remains unproven in humans. The compound shows reproducible anti-inflammatory and vasodilatory effects in vitro and in rodent models, but translating those findings into controlled clinical outcomes has remained difficult outside of rare disease applications.

VIP Is an Endogenous 28-Amino Acid Neuropeptide First Isolated from Porcine Intestine

Vasoactive intestinal peptide (VIP) is a naturally occurring peptide hormone discovered by Said and Mutt in 1970 during studies of porcine duodenal extracts. The name reflects its original characterization: it dilated blood vessels and was found in intestinal tissue. The peptide consists of 28 amino acids with a molecular weight of approximately 3,326 Da. Its amino acid sequence is highly conserved across mammalian species, with human and porcine VIP differing by only two residues.

VIP belongs to the secretin-glucagon peptide family, which includes structurally related hormones like PACAP, glucagon, and secretin. These peptides share a common evolutionary origin and structural motifs, particularly in their N-terminal regions. In humans, VIP is encoded by a single gene on chromosome 6 and is synthesized as part of a larger precursor protein (prepro-VIP) that also contains the related peptide PHM-27 (peptide histidine methionine).

The peptide is produced throughout the nervous system and in various peripheral tissues. It functions as both a neurotransmitter and a hormone, secreted by neurons in the central and peripheral nervous systems as well as by immune cells and endocrine cells in the gut and respiratory tract. Circulating VIP levels are typically low (under 50 pg/mL in healthy individuals) but rise significantly in response to certain physiological and pathological states.

VIP Signals Through VPAC1 and VPAC2 Receptors to Activate Adenylyl Cyclase and Downstream Anti-Inflammatory Pathways

VIP exerts its effects by binding to two high-affinity G protein-coupled receptors: VPAC1 (VIPR1) and VPAC2 (VIPR2). Both receptors are widely expressed across the immune system, nervous tissue, smooth muscle, and epithelial cells. A third receptor, PAC1, binds PACAP with higher affinity but can also respond to VIP at higher concentrations. VPAC receptors couple primarily to Gs proteins, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). This triggers protein kinase A (PKA) activation, which phosphorylates downstream transcription factors like CREB.

The cAMP-PKA pathway is central to VIP's anti-inflammatory effects. In vitro studies using human macrophages and dendritic cells show that VIP treatment suppresses pro-inflammatory cytokine production, including TNF-α, IL-6, and IL-12, while promoting release of anti-inflammatory IL-10. This shift is mediated in part by inhibition of NF-κB activation and upregulation of cAMP response element binding protein (CREB).

VIP also modulates T cell differentiation. Rodent studies demonstrate that VIP exposure shifts CD4+ T cells away from Th1 and Th17 phenotypes (which drive inflammatory responses) toward Th2 and regulatory T cell (Treg) phenotypes. In murine models of experimental autoimmune encephalomyelitis (an MS model), exogenous VIP administration reduced disease severity and CNS inflammation, associated with increased Tregs and decreased Th1/Th17 cells in the spinal cord.

Vasodilation occurs through direct smooth muscle relaxation, mediated by cAMP-induced reductions in intracellular calcium and activation of myosin light chain phosphatase. In isolated human bronchial smooth muscle, VIP causes dose-dependent relaxation with an EC50 in the nanomolar range. This mechanism underlies its bronchodilator and vasodilatory properties.

Rodent Models Show Consistent Anti-Inflammatory Effects, But Controlled Human Data Remains Limited Outside Rare Disease Contexts

Most VIP research has been conducted in cell culture and rodent models. In vitro, VIP demonstrates potent immunomodulatory effects at concentrations ranging from 1 to 100 nM. It inhibits LPS-induced cytokine release from human monocytes, reduces dendritic cell maturation, and suppresses T cell activation across multiple independent laboratories.

In rodent models of inflammatory disease, exogenous VIP has shown protective effects in colitis, arthritis, sepsis, and neuroinflammation models. In a murine dextran sulfate sodium (DSS) colitis model, intraperitoneal VIP administration (25 nmol/kg daily) reduced histological inflammation scores, improved survival, and decreased pro-inflammatory cytokine expression in colonic tissue. Similar protective effects have been reported in murine models of rheumatoid arthritis, where VIP reduced joint swelling and bone erosion when administered early in disease progression.

Human data is more limited. The most robust clinical evidence comes from a Phase II randomized controlled trial in sarcoidosis, a chronic inflammatory disease. Patients inhaled synthetic VIP (100 μg three times daily) for 6 months. The treatment group showed improved pulmonary function and reduced inflammatory markers compared to placebo, with minimal adverse effects. However, the study was relatively small (n=20) and has not been followed by larger confirmatory trials.

A Phase II trial in pulmonary arterial hypertension (PAH) tested inhaled VIP at escalating doses up to 200 μg four times daily. The study showed trends toward hemodynamic improvement but did not meet its primary endpoint for statistical significance. Post-hoc analysis suggested potential benefit in a subgroup of patients, but the results were not conclusive enough to advance to Phase III.

Attempts to use VIP in other inflammatory conditions (such as Crohn's disease and rheumatoid arthritis) have yielded mixed or inconclusive results in small pilot studies. Systemic delivery faces challenges due to VIP's extremely short half-life and rapid enzymatic degradation.

Therapeutic Use Is Limited by a Half-Life Under Two Minutes and Rapid Enzymatic Degradation

VIP has a plasma half-life of approximately 1 to 2 minutes in humans, degraded primarily by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP). This makes systemic administration impractical for sustained effects. Intravenous infusion produces transient vasodilation and smooth muscle relaxation, but circulating levels return to baseline within minutes after cessation.

Intranasal and inhaled administration routes have been explored to bypass first-pass degradation and deliver VIP directly to mucosal surfaces or the lungs. Intranasal VIP reaches the cerebrospinal fluid in animal models, suggesting potential CNS penetration, though human pharmacokinetic data is sparse. Inhaled VIP achieves local pulmonary concentrations sufficient for bronchodilation and may reduce systemic degradation, though absorption into circulation remains limited.

Research dosing in published rodent studies typically ranges from 10 to 50 nmol/kg delivered intraperitoneally or subcutaneously, often requiring multiple daily doses to sustain effects. In human trials, inhaled doses have ranged from 25 to 200 μg per administration, delivered 2 to 4 times daily. For research purposes only, VIP is typically reconstituted in sterile water or saline and stored frozen to prevent degradation.

Analogs with extended half-lives have been developed. These include modifications that resist DPP-IV cleavage or pegylation to increase molecular weight. Some analogs show improved stability in rodent models, but most have not advanced to human testing. Another approach involves using selective VPAC receptor agonists with better pharmacokinetics, though these are still in early development.

Stability is a concern in storage and handling. VIP degrades rapidly at room temperature and neutral pH. Lyophilized peptide should be stored at -20°C or colder. Once reconstituted, solutions should be used within hours or stored at -80°C in aliquots to avoid freeze-thaw cycles, which promote aggregation and fragmentation.

FAQ

Q: Is VIP the same as vasoactive intestinal polypeptide?

Yes, "vasoactive intestinal peptide" and "vasoactive intestinal polypeptide" refer to the same molecule. The abbreviation VIP is standard in the literature. The original naming reflects its discovery in intestinal extracts and its vasodilatory properties, though it is now recognized as a broadly distributed neuropeptide with immune and endocrine functions.

Q: Can VIP cross the blood-brain barrier?

Intact VIP does not readily cross the blood-brain barrier due to its size and hydrophilicity. However, intranasal administration may deliver VIP to the CNS via olfactory and trigeminal pathways, as demonstrated in rodent models where intranasal VIP increased CSF levels and reduced neuroinflammation. Whether clinically meaningful CNS concentrations are achieved in humans via this route remains unclear.

Q: What is the difference between VIP and PACAP?

Both are members of the secretin-glucagon peptide family and share structural similarity, particularly in their N-terminal regions. PACAP (pituitary adenylate cyclase-activating polypeptide) binds with high affinity to PAC1 receptors and also activates VPAC1 and VPAC2. VIP preferentially binds VPAC receptors. They have overlapping but distinct physiological roles, with PACAP showing stronger neuroprotective effects in some models and VIP showing more potent anti-inflammatory activity in others.

Q: Why hasn't VIP been approved as a therapeutic despite decades of research?

The primary barrier is pharmacokinetics. VIP's half-life of 1 to 2 minutes makes sustained therapeutic levels difficult to achieve without continuous infusion or frequent dosing. Most clinical trials have struggled to demonstrate efficacy at tolerable dosing frequencies, and development of longer-acting analogs has been slow. The one approved indication (VIPoma diagnosis) uses VIP as a biomarker, not a therapeutic agent.

Q: Are there any FDA-approved uses of VIP?

No VIP-based therapies are FDA-approved for treatment. VIP radioimmunoassay is used diagnostically to measure plasma VIP levels in suspected VIPoma (a rare tumor that secretes excessive VIP). Research use remains the primary context for synthetic VIP in studies of inflammation, pulmonary disease, and neuroprotection.

Medical Disclaimer: This article is for informational and research reference purposes only. VIP is not approved by the FDA for therapeutic use in any condition. The information presented does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare provider before considering any research compound.